Anika Therapeutics, Inc. Accounts Receivable, Allowance for Credit Loss
Anika Therapeutics, Inc. (ANIK) had Accounts Receivable, Allowance for Credit Loss of $600.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-07-29
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $600.00K.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $1.09M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $1.13M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $870.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $1.09M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $1.13M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $870.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $799.00K 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $716.00K 10-Q · filed 2026-04-30 | |
| 2024-12-31 | $730.00K 10-Q · filed 2026-07-29 | |
| 2024-09-30 | $677.00K 10-Q · filed 2025-11-05 | $2.57M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $653.00K 10-Q · filed 2025-07-30 | $1.63M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $818.00K 10-Q · filed 2025-05-09 | $1.66M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $666.00K 10-K · filed 2026-03-03 | $1.62M 10-K · filed 2024-03-15 |
| 2023-09-30 | $1.57M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $1.54M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $821.00K 10-K · filed 2026-03-03 | $1.61M 10-K · filed 2023-03-16 |
| 2022-09-30 | $1.57M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $1.41M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $1.35M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $941.00K 10-K · filed 2025-03-17 | $1.44M 10-K · filed 2022-03-11 |
| 2020-12-31 | $1.52M 10-K · filed 2024-03-15 | |
| 2019-12-31 | $962.00K 10-K · filed 2023-03-16 | |
| 2018-12-31 | $1.52M 10-K · filed 2022-03-11 | |
| 2017-12-31 | $1.91M 10-K/A · filed 2021-04-26 | |
| 2016-12-31 | $194.00K 10-K · filed 2020-03-06 | |
| 2015-12-31 | $167.00K 10-K · filed 2019-02-27 | |
| 2014-12-31 | $147.00K 10-K · filed 2018-02-27 | $146.62K 10-K · filed 2015-03-13 |
| 2013-12-31 | $593.00K 10-K · filed 2017-02-24 | $593.02K 10-K · filed 2014-03-13 |
| 2012-12-31 | $337.00K 10-K · filed 2016-03-10 | $337.46K 10-K · filed 2014-03-13 |
| 2011-12-31 | $334.47K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |